Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.960
+0.030 (1.02%)
Aug 11, 2025, 1:38 PM - Market open
Paramount Global Revenue
Lipocine had revenue of $622.85K in the quarter ending June 30, 2025, with 595.42% growth. This brings the company's revenue in the last twelve months to $4.21M, down -12.35% year-over-year. In the year 2024, Lipocine had annual revenue of $11.20M, down -492.80%.
Revenue (ttm)
$4.21M
Revenue Growth
-12.35%
P/S Ratio
3.72
Revenue / Employee
$263,007
Employees
16
Market Cap
16.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.20M | 14.05M | -492.80% |
Dec 31, 2023 | -2.85M | -3.35M | -670.16% |
Dec 31, 2022 | 500.00K | -15.64M | -96.90% |
Dec 31, 2021 | 16.14M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LPCN News
- 6 days ago - Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PRNewsWire
- 6 weeks ago - Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - PRNewsWire
- 7 weeks ago - Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - PRNewsWire
- 2 months ago - Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PRNewsWire
- 2 months ago - Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - PRNewsWire
- 3 months ago - Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - PRNewsWire
- 3 months ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - PRNewsWire
- 3 months ago - Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - PRNewsWire